Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7241-7250 Newer>

The Motley Fool March 11, 2011 Brian Orelli	Johnson & Johnson Gets a Slap on the Wrist The consent decree could have been a lot worse.
The Motley Fool March 11, 2011 Brian Orelli	Sales Can Quadruple, More to Come Dendreon is still supply-constrained, but less than before.
The Motley Fool March 11, 2011 Travis Hoium	KV Pharmaceutical Shares Plunged Temporarily: What You Need to Know Shares of drugmaker KV Pharmaceutical fell as much as 14% in a wild ride that currently has the stock trading flat from yesterday's close.
The Motley Fool March 11, 2011 Brian D. Pacampara	Emergent BioSolutions Shares Plunged: What You Need to Know Shares of biotechnology company Emergent BioSolutions experienced heavy volatility in early trading after reporting its quarterly results.
BusinessWeek March 10, 2011 Kanoko Matsuyama	From Soup to MS Drug: One Fungus's Journey Gilenya, Mitsubishi Tanabe's parasite-derived pill for multiple sclerosis, could be a blockbuster.
The Motley Fool March 9, 2011 Brian Orelli	Slicing and Dicing Your Way through Drug Development The drug developer announces that it licensed the Japanese rights to perifosine, its lead cancer drug, to Yakult Honsha.
The Motley Fool March 9, 2011 Seth Jayson	Does This Mean Align Technology Will Burn You? For the last fully reported fiscal quarter, Align Technology's year-over-year revenue grew 7.2%, and its AR grew 20%. That's a yellow flag.
Chemistry World March 8, 2011 Andy Extance	GSK will pay off UK graduate tuition fees Potential undergraduate chemistry students concerned about their prospects in the face of plant closures and increased tuition fees have been given some cheer by pharmaceutical giant GlaxoSmithKline.
The Motley Fool March 8, 2011 Seth Jayson	Should You Get Out of Hill-Rom Holdings Before Next Quarter? For the last fully reported fiscal quarter, Hill-Rom Holdings's year-over-year revenue grew 5.3%, and its AR grew 1.9%. That looks OK.
The Motley Fool March 7, 2011 Brian Orelli	Kids, Vaccines, and Deaths a Bad Combination Pfizer and Sanofi may not to be to blame, but when investing in drugmakers, you always have to be worried about drug safety. Fortunately this doesn't look like one of those issues.
<Older 7241-7250 Newer> Return to current articles.